NanoViricides (NYSE:NNVC) Coverage Initiated at StockNews.com

Equities research analysts at StockNews.com started coverage on shares of NanoViricides (NYSE:NNVC – Get Rating) in a research report issued to clients and investors on Monday. The firm set a “sell” rating on the stock.

NanoViricides Price Performance

NNVC stock opened at $1.16 on Monday. NanoViricides has a 52 week low of $1.05 and a 52 week high of $3.88. The firm has a market cap of $13.50 million, a price-to-earnings ratio of -1.93 and a beta of 1.07.

About NanoViricides

(Get Rating)

NanoViricides, Inc is a development stage company, which engages in the development of nanomedicine drugs against viruses. It focuses on anti-viral therapeutics and is seeking to add to its existing portfolio of products through its internal discovery and clinical development programs. The company was founded by Anil R.